DMAC News and Press, DiaMedica Therapeutics Inc. From 08/05/20

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today that it intends to offer and sell its common shares in an underwritten public offering. In addition, DiaMedica intends to grant the underwriters a 30-day option to purchase up to an additional ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 17th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, May 27, 2020. Management will be available to participate in one-on-one meetings. Meetings will take pl...

The following slide deck was published by DiaMedica Therapeutics Inc. in conjunction with their 2020 Q1 earnings Read more ...

Gainers:  Applied DNA Sciences (NASDAQ: APDN ) +51% . More news on: Applied DNA Sciences, Inc., Akers Biosciences, Inc., Glory Star New Media Group Holdings Limited, Stocks on the move, , Read more ...

DiaMedica Therapeutics Inc. (DMAC) Q1 2020 Results Earnings Conference Call May 14, 2020, 08:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer Scott Kellen - Chief Financial Officer Harry Alcorn - Chief Medical Officer Conference Call Participants ...

Thinly traded nano cap DiaMedica (NASDAQ: DMAC ) announces positive topline results from a Phase 2 clinical, ReMEDy , evaluating DM199 in acute ischemic stroke patients. More news on: DiaMedica Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...

DiaMedica Therapeutics (NASDAQ: DMAC ): Q1 GAAP EPS of -$0.19 beats by $0.09 . More news on: DiaMedica Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

DM199 Met Primary Safety and Tolerability Endpoints in ReMEDy Study Top-Line Data Demonstrated Therapeutic Effect in Participants Not Pre-Treated With Mechanical Thrombectomy Reduced Risk of Recurrent Stroke Results Consistent With Clinical Studies of Approved Uri...

DM199 Met Primary Safety and Tolerability Endpoints in ReMEDy Study Top-Line Data Demonstrated Therapeutic Effect in Patients Not Pre-treated with Mechanical Thrombectomy DiaMedica Completes $8.5M Public Offering of Common Shares Cash and Investments of $12.6 Mill...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2020 financial results will be released after the markets close on Wednesday, May 13 th . DiaMedica will host a live conference call on Thursday, May 14 th at 7:00 AM Central Time to discuss its business update...